Industries > Pharma > Global Allergic Rhinitis Drugs Market 2017-2027
Global Allergic Rhinitis Drugs Market 2017-2027
Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines
The global allergic rhinitis drugs market is expected to grow at a CAGR of 3.2% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.3% from 2016-2027. The market is estimated at $11.9bn in 2016 and $13.9bn in 2021.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 255-page report you will receive 85 tables and 88 figures – all unavailable elsewhere.
The 255-page report provides clear detailed insight into the global allergic rhinitis drugs market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Allergic Rhinitis Drugs Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for allergic rhinitis drugs, our investigation shows forecasts to 2027 for the following submarkets:
– Intranasal Antihistamines
– Intranasal Corticosteroids
– Oral Antihistamines
– Immunotherapy and Vaccines
• How will leading allergic rhinitis drugs perform to 2027 at world level? Our study forecasts individual revenues of these 27 products:
– Patanase
– Astepro
– Astelin
– Dymista
– Nasonex
– Avamys
– Veramyst
– Flixonase
– Rhinocort
– Omnaris
– Nasacort
– Beconase
– Qnasl
– Zetonna
– Allegra
– Zyrtec
– Claritin
– Xyzal
– Allelock
– Clarinex
– Ebastel
– Talion
– Staloral
– Alutard SQ
– Grazax
– Ragwitek
– Generic Azelastine
• This report provides individual revenue forecasts to 2027 for these regional and national markets:
– US
– EU5 – Germany, UK, France, Italy and Spain
– China
– Japan
– India
– Russia
– Brazil
– Rest of the World
• Our work provides analysis and sales forecast of the leading companies in the allergic rhinitis drugs market:
– GlaxoSmithKline (GSK)
– Merck & Co
– Sanofi
– Johnson & Johnson
– ALK-Abello
– UCB
– Kyowo Hako Kirin
– Stallergenes Greer
• This report discusses the trends and development in the allergic rhinitis pipeline
• Our study discusses strengths, weaknesses, opportunities and threats as well as porter’s five forces analysis of the global allergic rhinitis drugs market
Visiongain’s study is intended for anyone requiring commercial analyses for the global allergic rhinitis drugs market. You find data, trends and predictions.
Buy our report today Global Allergic Rhinitis Drugs Market 2017-2027: Oral Antihistamines, Intranasal Corticosteroids, Intranasal Antihistamines, Immunotherapy and Vaccines.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Allergic Rhinitis Drugs: Market Overview
1.2 Global Allergic Rhinitis Drugs Market Segmentation
1.3 Overview of Findings
1.4 Structure of the Report
1.5 Why You Should Read This Report
1.6 How This Report Delivers
1.7 Key Questions Answered by This Analytical Report
1.8 Who is This Report For?
1.9 Methodology
1.10 Frequently Asked Questions (FAQ)
1.11 Associated Visiongain Reports
1.12 About Visiongain
2. An Introduction to Allergic Rhinitis Drugs
2.1 The Pharmaceutical Industry: A Brief Introduction
2.1.1 Allergic Rhinitis Treatments – An Industry Overview
2.2 A Brief Overview of Allergy
2.3 Allergic Rhinitis
2.3.1 The Global Prevalence of Allergic Rhinitis
2.3.2 Pathophysiology of Allergic Rhinitis: IgEs and Mast Cells
2.3.3 Symptoms of Allergic Rhinitis
2.3.4 Classification of Allergic Rhinitis
2.3.4.1 Non-Allergic Rhinitis and Mixed Rhinitis
2.3.5 Seasonal Allergic Rhinitis (Hay Fever)
2.3.6 Perennial Allergic Rhinitis
2.3.7 Diagnosis of Allergic Rhinitis
2.4 Treatment of Allergic Rhinitis
2.4.1 Antihistamines
2.4.1.1 First-Generation Antihistamines
2.4.1.2 Second- and Third-Generation Antihistamines
2.4.2 Corticosteroids
2.4.2.1 First-, Second- and Third-Generation Intranasal Corticosteroids
2.4.2.2 Combination Drug Products
2.4.3 Leukotriene Receptor Antagonists
2.4.4 Cromolyn (cromoglicic acid)
2.4.5 Decongestants
2.4.6 Saline Nasal Sprays
2.4.7 Immunotherapy and Vaccines
2.5 Phases of Clinical Trials
2.6 Scope of this Report
3. The Global Allergic Rhinitis Drugs Market, 2017-2027
3.1 The Global Allergic Rhinitis Drugs Market: Market Overview
3.2 Categorisation of The Global Allergic Rhinitis Drugs Market
3.3 The Global Allergic Rhinitis Drugs Market in 2016
3.4 The Global Allergic Rhinitis Drugs Market: Market Forecast 2017-2027
3.5 Allergic Rhinitis Drugs: Changing Market Shares by Sector 2017-2027
4. Oral Antihistamines Market: Market Analysis and Forecast 2017-2027
4.1 Oral Antihistamines: Market Overview
4.1.1 Leading Products in the Oral Antihistamines Market, 2016
4.2 Oral Antihistamines: Market Trends and Developments, 2017
4.2.1 Patent Expiries and the Threat of Generics
4.2.2 The Increasing Switch from Prescription to Over-The-Counter Sales
4.2.3 The Potential for Combination Therapy with Intranasal Corticosteroids
4.3 Oral Antihistamines: Market Forecast 2017-2027
4.3.1 Oral Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
4.4 Leading Oral Antihistamines for the Treatment of Allergic Rhinitis
4.4.1 Allegra/Allegra-D/Allegra OTC (fexofenadine) - Sanofi
4.4.1.1 Allegra/Allegra OTC: Historical Sales, 1995-2014
4.4.1.2 Allegra/Allegra OTC: Sales Forecast 2016-2027
4.4.2 Claritin/Claritin OTC (loratadine) – Bayer/ Merck & Co
4.4.2.1 Claritin/Claritin OTC: Sales Forecast 2017-2027
4.4.3 Zyrtec/Zyrtec D (cetirizine) - Johnson & Johnson/ UCB/ GSK
4.4.3.1 Zyrtec/Zyrtec D: Sales Forecast 2017-2027
4.4.4 Xyzal (levocetirizine) - Sanofi/ UCB/ GSK
4.4.4.1 Xyzal: Sales Forecast 2017-2027
4.4.5 Clarinex (desloratadine) - Merck & Co.
4.4.5.1 Clarinex: Sales Forecast 2017-2027
4.4.6 Allelock (olopatadine) - Kyowa Hakko Kirin
4.4.6.1 Allelock: Sales Forecast 2017-2027
4.4.7 Ebastel (ebastine) - AstraZeneca/Takeda/Dainippon Sumitomo
4.4.7.1 Ebastel: Sales Forecast 2017-2027
4.4.8 Talion (bepotastine) - Mitsubishi Tanabe
4.4.8.1 Talion: Sales Forecast 2017-2027
4.4.9 Other Oral Antihistamines: Sales Forecast 2017-2027
5. Intranasal Corticosteroids Market: Market Analysis and Forecast 2017-2027
5.1 Leading Products in the Intranasal Corticosteroids Market, 2016
5.2 Intranasal Corticosteroids: Market Forecast 2017-2027
5.2.1 Intranasal Corticosteroids: Changing Market Shares by Leading Drugs 2017-2027
5.3 Leading Intranasal Corticosteroids
5.3.1 Flixonase/Flonase/Flonase-OTC (fluticasone propionate) - GlaxoSmithKline
5.3.1.1 Flixonase/Flonase/Flonase-OTC Forecast, 2017-2027
5.3.2 Nasonex (mometasone) - Merck
5.3.2.1 Nasonex Forecast, 2017-2027
5.3.3 Avamys/Veramyst (fluticasone furoate) - GlaxoSmithKline
5.3.3.1 Avamys/Veramyst Forecast, 2017-2027
5.3.4 Rhinocort (budesonide) - AstraZeneca
5.3.4.1 Rhinocort Forecast, 2017-2027
5.3.5 Nasacort/Nasacort-OTC (triamcinolone) - Sanofi
5.3.5.1 Nasacort/Nasacort-OTC Forecast, 2017-2027
5.3.6 Omnaris (ciclesonide) - Dainippon Sumitomo/Takeda
5.3.6.1 Omnaris: Sales Forecast, 2017-2027
5.3.7 Beconase/Beconase AQ (beclometasone) - GlaxoSmithKline/Omega Pharma
5.3.7.1 Beconase/Beconase AQ Forecast, 2017-2027
5.3.8 Qnasl (beclometasone) - Teva
5.3.8.1 Qnas Forecast, 2017-2027
5.3.9 Zetonna (ciclesonide) - Dainippon Sumitomo
5.3.9.1 Zetonna Forecast, 2017-2027
6. Immunotherapy and Vaccines: Market Analysis and Forecast 2017-2027
6.1 Immunotherapy and Vaccines: Market Overview
6.1.1 Immunotherapy: Primed for Rapid Expansion
6.2 Leading Immunotherapy Products in the Allergic Rhinitis Market, 2016
6.3 Allergic Rhinitis Immunotherapy: Market Trends and Developments, 2016
6.3.1 Subcutaneous and Sublingual Immunotherapy
6.3.2 Expansion into the US Market
6.3.3 Standardisation of Immunotherapy Products
6.3.4 Immunotherapy as a Preventative Treatment
6.4 Allergic Rhinitis Immunotherapy: Market Forecast 2017-2027
6.4.1 Allergic Rhinitis Immunotherapy: Changing Market Shares by Leading Products 2017-2027
6.5 Immunotherapy Type – By Route of Administration, 2016
6.6 Leading Immunotherapy Products for Allergic Rhinitis
6.6.1 Staloral (Grass pollen allergen extract) - Stallergenes
6.6.1.1 Staloral: Sales Forecast 2017-2027
6.6.2 Alutard SQ (Grass pollen allergen extract) - ALK-Abelló
6.6.2.1 Alutard SQ: Sales Forecast 2017-2027
6.6.3 Grazax/Grastek (Timothy grass pollen allergen extract) - ALK-Abelló/Merck
6.6.3.1 Grazax/Grastek: Sales Forecast 2016-2027
6.6.4 Oralair (Grass pollen allergen extract) - Stallergenes/Greer
6.6.4.1 Oralair: Sales Forecast 2017-2027
6.6.5 Ragwitek (Short ragweed pollen allergen extract) - Merck
6.6.5.1 Ragwitek: Sales Forecast 2017-2027
6.6.6 Other Allergic Rhinitis Immunotherapy Products: Sales Forecast 2017-2027
7. The Intranasal Antihistamines Market: Market Analysis and Forecast 2017-2027
7.1 Leading Products in the Intranasal Antihistamines Market, 2016
7.2 Intranasal Antihistamines: Market Trends and Developments, 2017
7.2.1 Azelastine versus Olopatadine
7.2.2 Intranasal Combination Products
7.3 Intranasal Antihistamines: Market Forecast 2017-2027
7.3.1 Intranasal Antihistamines: Changing Market Shares by Leading Drugs 2017-2027
7.4 Leading Intranasal Antihistamines
7.4.1 Dymista (azelastine/fluticasone) - Meda Pharmaceuticals
7.4.1.1 Mylan Acquires Meda Pharmaceuticals
7.4.1.2 Dymista: Sales Forecast 2017-2027
7.4.2 Generic Intranasal Azelastine
7.4.2.1 Generic Intranasal Azelastine: Sales Forecast, 2017-2027
7.4.3 Astepro (azelastine) – Meda Pharmaceuticals
7.4.3.1 Astepro: Sales Forecast 2016-2027
7.4.4 Patanase (olopatadine) - Novartis
7.4.4.1 Patanase: Sales Forecast 2016-2027
7.4.5 Astelin (azelastine) - Meda Pharmaceuticals
7.4.5.1 Astelin: Sales Forecast 2017-2027
8. Leading National Markets for Allergic Rhinitis Drugs, 2016-2027
8.1 The Allergic Rhinitis Drugs Market by Region
8.1.1 The Global Distribution of Allergic Rhinitis Drugs in 2016
8.2 Leading National Markets: Forecast 2016-2027
8.2.1 Changing Market Shares by Region, 2016-2027
8.3 Regional Allergic Rhinitis Drugs Markets: Analysis and Forecasts, 2016-2027
8.3.1 United States: The Largest Allergic Rhinitis Drugs Market
8.3.1.1 US Allergic Rhinitis Drugs Market: Trends and Developments
8.3.1.2 US Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.3.2 EU5
8.3.2.1 EU5 Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.3.2.2 EU5 Markets: Changing Market Shares by Country, 2016-2027
8.3.2.3 Germany
8.3.2.4 UK
8.3.2.5 France
8.3.2.6 Italy
8.3.2.7 Spain
8.4 China
8.4.1 Air Pollution Associated with Increasing Prevalence
8.4.2 Expansion of Healthcare Coverage and Reimbursement in China
8.4.3 China Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.5 Japan
8.5.1 Cedar Reforestation and the Hay Fever Epidemic
8.5.2 Genetically Modified Rice as Immunotherapy
8.5.3 Effects of the Rising Levels of Generic Drug Penetration
8.5.4 Japan Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.6 Russia
8.6.1 How Will Russia’s Economic Status Affect Its Pharma Industry?
8.6.2 Russia Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.7 India
8.7.1 The Impact of the Drug Prices Control Order on Indian Pharma
8.7.2 India’s Expansion of Healthcare Provision
8.7.3 India Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.8 Brazil
8.8.1 How Will Brazil’s Growing Healthcare Influence Allergic Rhinitis Drugs
8.8.2 Brazil Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
8.9 Rest of the World
8.9.1 Rest of the World Allergic Rhinitis Drugs Market: Market Forecast 2016-2027
9. Leading Companies in the Allergic Rhinitis Drugs Market, 2016-2027
9.1 Allergic Rhinitis Drugs – An Evolving Market Space
9.1.1 Leading Companies in the Allergic Rhinitis Drugs Market, 2016
9.2 ALK-Abelló
9.2.1 ALK-Abelló: Allergic Rhinitis Drugs Portfolio, 2017
9.2.2 ALK-Abelló: Recent Developments
9.2.2.1 ALK Acquired Allergy Laboratories, Inc. and Crystal Laboratory LLC to Strengthen Its Supply Chain Activities
9.2.2.2 ACARIZAX Launched in Europe progressing to International Roll-Out
9.2.2.3 ALK Collaborates with EddingPharm to Boost China Sales
9.2.2.4 ALK-Abelló: Sales Forecast 2016-2027
9.2.2.5 ALK-Abelló: Allergic Rhinitis Drug Development Pipeline, 2016
9.3 GlaxoSmithKline (GSK)
9.3.1 GlaxoSmithKline: Allergic Rhinitis Drugs Portfolio, 2017
9.3.2 GlaxoSmithKline: Sales Forecast 2016-2027
9.4 Johnson & Johnson
9.4.1 Johnson & Johnson: Allergic Rhinitis Drugs Portfolio, 2017
9.4.2 Johnson & Johnson: Recent Developments
9.4.2.1 Manufacturing Recalls at McNeil Consumer Healthcare
9.4.2.2 Johnson & Johnson: Sales Forecast 2016-2027
9.5 Kyowa Hakko Kirin
9.5.1 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Portfolio, 2017
9.5.2 Kyowa Hakko Kirin: Sales Forecast 2016-2027
9.6 Merck & Co.
9.6.1 Merck: Allergic Rhinitis Drugs Portfolio, 2017
9.6.2 Merck: Recent Developments
9.6.2.1 Bayer Acquires Merck’s Consumer Health Business
9.6.2.2 FDA Rejects Singulair OTC Switch
9.2.6.3 Merck: Sales Forecast 2016-2027
9.2.6.4 Merck: Allergic Rhinitis Drug Development Pipeline, 2017
9.7 Sanofi
9.7.1 Sanofi: Allergic Rhinitis Drugs Portfolio, 2017
9.7.2 Sanofi: Sales Forecast 2016-2027
9.7.3 Sanofi: Recent Developments
9.7.3.1 Sanofi Received US FDA Approval for Its Xyzal Allergy 24HR
9.8 Stallergenes Greer
9.8.1 Stallergenes: Allergic Rhinitis Drugs portfolio, 2017
9.8.2 Stallergenes Greer: Sales Forecast 2016-2027
9.8.3 Stallergenes Greer: Allergic Rhinitis Drug Development Pipeline, 2017
9.9 UCB
9.9.1 UCB: Allergic Rhinitis Drugs Portfolio, 2017
9.9.2 UCB: Sales Forecast 2016-2027
9.10 Other Leading Companies within the Allergic Rhinitis Drugs Market
10. Allergic Rhinitis Drugs: Research and Development Pipeline, 2016-2027
10.1 Trends and Developments in the Allergic Rhinitis Pipeline
10.2 The R&D Pipeline for Oral Antihistamines, 2017
10.2.1 Talion (bepotastine) - Mitsubishi Tanabe
10.2.2 ZPL-3893787 (histamine H4R antagonist) - Ziarco Pharma
10.3 The R&D Pipeline for Intranasal Corticosteroids, 2017
10.3.1 APC-3000 (HFA inhaled corticosteroid) - Adamis Pharmaceuticals
10.3.2 TBS-6 - Trimel Pharmaceuticals
10.4 The R&D Pipeline for Immunotherapy in Allergic Rhinitis, 2017
10.4.1 Actair (house dust mite SLIT; STG320) - Stallergenes/Shionogi & Co
10.4.2 AllerT (subcutaneous birch pollen immunotherapy) - Anergis
10.4.3 Depigoid Birch 5000 (birch pollen allergen extract, Leti Pharma
10.4.4 House Dust Mite SLIT-Tablet (MK-8237) - ALK-Abelló/Merck/Torii
10.4.5 Pollinex Quattro (subcutaneous immunotherapies) - Allergy Therapeutics
10.4.6 gp-ASIT+ (grass pollen allergen fragments) - Biotech Tools
10.4.7 Betula verrucosa (Bet v) 1 allergen – Stallergenes Greer
10.5 The R&D Pipeline for Other Allergic Rhinitis Drugs
10.5.1 S-555739 (prostaglandin D2 receptor antagonist) - Shionogi
10.5.2 DSP-3025/AZD-8848 (toll-like receptor 7 agonist) - Dainippon Sumitomo/ AstraZeneca
10.5.3 GSK2245035 (toll-like receptor 7 agonist) - GSK
10.5.4 HP-3060 (transdermal long-acting tape) - Hisamitsu
10.5.5 MRX-4 (anti-inflammatory agent) - Celsus Therapeutics
11. Qualitative Analysis of the Allergic Rhinitis Drugs Market, 2016-2027
11.1 Market Factors Influencing Allergic Rhinitis Drugs
11.2 SWOT Analysis of The Global Allergic Rhinitis Drugs Market, 2016-2027
11.2.1 Strengths
11.2.1.1 OTC-Switch Facilitating Ease of Consumer Access
11.2.1.2 The Established Role of Allergic Rhinitis Drugs in Treatment
11.2.1.3 Allergic Rhinitis and Rising Unmet Clinical Need
11.2.1.4 Rising Profile of Allergic Rhinitis in Various Regions Driving Healthcare Provision
11.2.2 Weaknesses
11.2.2.1 Intranasal Corticosteroids and Patients’ Satisfaction Rates
11.2.2.2 Increasing Penetration of Generic Drug Products
11.2.2.3 The Challenge Raised by The Low Volume of Pipeline Developments
11.2.3 Opportunities
11.2.3.1 Growth in Emerging Markets Outstripping Established Markets
11.2.3.2 Rx-to-OTC Switching and The Effects on Revenue Potential
11.2.3.3 Combination Drug Products Providing Rising Efficacy Profiles
11.2.3.4 The Emergence of Immunotherapy in Allergic Rhinitis
11.2.4 Threats
11.2.4.1 Cost-Containment as A Growth Restraint
11.2.4.2 Rising Cost of APIs and Manufacturing
11.2.4.3 Patent Expiries and The Resultant Loss of Revenue
11.3 Porter’s Five Forces Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027
11.3.1 Power of Buyers
11.3.2 Power of Suppliers
11.3.3 Threat of Substitutes
11.3.4 Threat 0f New Entrants
11.3.5 Rivalry Among Competitors
12. Conclusion
12.1 Overview of Current Market Conditions and Market Forecast, 2016-2027
12.2 Leading Sectors in the Allergic Rhinitis Drugs Market in 2016
12.3 Leading Regions in the Allergic Rhinitis Drugs Market in 2016
12.4 Leading Companies in the Allergic Rhinitis Drugs Market, 2016
12.5 What Does the Future Hold for Allergic Rhinitis Drugs?
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 1.1 (Sample) Allergic Rhinitis Market Forecast by National Market: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 2.1 Leading Antihistamines for Allergic Rhinitis, 2017
Table 2.2 Leading Corticosteroids for Allergic Rhinitis, 2017
Table 2.3 Clinical Trial Phases
Table 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2016
Table 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
Table 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016, 2021, 2027
Table 4.1 Leading Oral Antihistamines: Revenue ($m) and Market Share (%), 2016
Table 4.2 Oral Antihistamines Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 The Global Oral Antihistamines Market: Market Share (%), 2016, 2021, 2027
Table 4.4 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.5 Claritin/Claritin OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Zyrtec/Zyrtec-D Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.7 Xyzal Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 4.8 Clarinex Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 4.9 Allelock Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.10 Ebastel Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.11 Talion Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.12 Other Oral Antihistamines Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m) and Market Shares (%), 2016
Table 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2027
Table 5.3 The Global Intranasal Corticosteroids Market: Market Share (%), 2016, 2021, 2027
Table 5.4 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 5.5 Nasonex Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.6 Avamys/Veramyst Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.7 Rhinocort: Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.8 Nasacort/Nasacort-OTC Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.9 Omnaris Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.10 Beconase/Beconase AQ Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.11 Qnasl Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 5.12 Zetonna Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m) and Market Share (%), 2016
Table 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016, 2021, 2027
Table 6.4 Allergic Rhinitis Immunotherapy Market by Type: Revenue ($m) and Market Share (%), 2016
Table 6.5 Staloral Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.6 Alutard SQ Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.7 Grazax/Grastek Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 6.8 Oralair Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.9 Ragwitek Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 6.10 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.1 Top Drugs In The Intranasal Antihistamines Market: Revenue ($m) and Market Shares (%), 2016
Table 7.2 Intranasal Antihistamines Market Forecast by Leading Drugs: Revenue ($m), AGR (%), and CAGR%), 2016-2027
Table 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016, 2021, 2027
Table 7.4 Dymista (Meda Pharma) Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.5 Generic Intranasal Azelastine Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.6 Astepro Forecast; Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.7 Patanase Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 7.8 Astelin Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m) and Market Share (%), 2016
Table 8.2 Global Allergic Rhinitis Drugs Market Forecast by Region: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016, 2021, and 2027
Table 8.4 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.5 The EU5 Allergic Rhinitis Drugs Market Forecast by Country: Revenue ($m) and Market Share (%), 2016
Table 8.6 The EU5 Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 8.7 The EU5 Allergic Rhinitis Drugs Market by Country: Market Share (%), 2016, 2021, 2027
Table 8.8 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.9 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.10 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.11 Italy Allergic Rhinitis Drugs Market Forecat: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.12 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.13 China Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 8.14 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%), and CAGR (%), 2016-2027
Table 8.15 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.16 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.17 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 8.18 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue($m), AGR (%) and CAGR (%), 2016-2027
Table 9.1 Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m) and Market Shares (%), 2016
Table 9.2 ALK- Abelló: Company Overview, 2017
Table 9.3 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.4 GlaxoSmithKline: Company Overview, 2017
Table 9.5 GlaxoSmithKline: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.6 Johnson & Johnson: Company Overview, 2017
Table 9.7 Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.8 Kyowa Hakko Kirin: Company Overview, 2017
Table 9.9 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027
Table 9.10 Merck & Co.: Company Overview, 2017
Table 9.11 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.12 Sanofi: Company Overview, 2017
Table 9.13 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.14 Stallergenes Greer: Company Overview, 2016
Table 9.15 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 9.16 UCB: Company Overview, 2017
Table 9.17 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
Table 11.1 SWOT Analysis of the Global Allergic Rhinitis Drugs Market, 2016-2027
List of Figures
Figure 1.1 Global Allergic Rhinitis Drugs Market: Market Sectors, 2017
Figure 2.1 Role of Mast Cells and IgE in Allergic Rhinitis, 2017
Figure 3.1 The Global Allergic Rhinitis Drugs Market: Revenue ($m) by Sector, 2016
Figure 3.2 The Global Allergic Rhinitis Drugs Market: Market Forecast ($m, AGR%) by Sector, 2016-2027
Figure 3.3 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2016
Figure 3.4 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2021
Figure 3.5 The Global Allergic Rhinitis Drugs Market: Market Share (%) by Sector, 2027
Figure 4.1 Leading Oral Antihistamines: Revenue ($m), 2016
Figure 4.2 Oral Antihistamines Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.3 The Global Oral Antihistamines Market: Market Share (%), 2016
Figure 4.4 The Global Oral Antihistamines Market: Market Share (%), 2021
Figure 4.5 The Global Oral Antihistamines Market: Market Share (%), 2027
Figure 4.6 Allegra (Allegra Rx and Allegra OTC) Historical Sales: Revenue ($m),1995-2016
Figure 4.7 Allegra/Allegra-D/Allegra OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.8 Claritin/Claritin OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.9 Zyrtec/Zyrtec-D Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.10 Xyzal Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.11 Clarinex Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.12 Allelock Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.13 Ebastel Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 4.14 Talion Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 4.15 Other Oral Antihistamines Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.1 Leading Drugs In The Intranasal Corticosteroids Market: Revenue ($m), 2016
Figure 5.2 Intranasal Corticosteroids Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.3 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2016
Figure 5.4 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2021
Figure 5.5 The Global Intranasal Corticosteroids Market by Leading Drugs: Market Share (%), 2027
Figure 5.6 Flixonase/Flonase/Flonase-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.7 Nasonex Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.8 Avamys/Veramyst Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.9 Rhinocort Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.10 Nasacort/Nasacort-OTC Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.11 Omnaris Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.12 Beconase/Beconase AQ Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.13 Qnasl Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 5.14 Zetonna Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.1 Leading Allergic Rhinitis Immunotherapy Products: Revenue ($m), 2016
Figure 6.2 Allergic Rhinitis Immunotherapy Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.3 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2016
Figure 6.4 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2021
Figure 6.5 The Global Allergic Rhinitis Immunotherapy Market: Market Share (%), 2027
Figure 6.6 Allergic Rhinitis Immunotherapy Market: Market Share (%) by Immunotherapy Type, 2016
Figure 6.7 Staloral Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.8 Alutard SQ Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 6.9 Grazax/Grastek Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 6.10 Oralair Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.11 Ragwitek Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 6.12 Other Allergic Rhinitis Immunotherapy Products Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.1 Top Drugs in The Intranasal Antihistamines Market: Revenue ($m), 2016
Figure 7.2 Intranasal Antihistamines Market Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 7.3 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2016
Figure 7.4 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2021
Figure 7.5 The Global Intranasal Antihistamines Market by Leading Drugs: Market Share (%), 2027
Figure 7.6 Dymista (Meda Pharma) Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 7.7 Generic Intranasal Azelastine Forecast: Revenue ($m) and, AGR (%), 2016-2027
Figure 7.8 Astepro Forecast: Revenue ($m), and AGR (%), 2016-2027
Figure 7.9 Patanase Forecast: Revenue($m) and AGR (%), 2016-2027
Figure 7.10 Astelin Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 8.1 The Global Allergic Rhinitis Drugs Market by Region: Revenue ($m), 2016
Figure 8.2 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2016
Figure 8.3 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2021
Figure 8.4 The Global Allergic Rhinitis Drugs Market Forecast by Region: Market Share (%), 2027
Figure 8.5 US Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.6 The EU5 Allergic Rhinitis Drugs Market by Country: Revenue ($m), 2016
Figure 8.7 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2016
Figure 8.8 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2021
Figure 8.9 The EU5 Allergic Rhinitis Drugs Market: Market Share (%), 2027
Figure 8.10 Germany Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.11 UK Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.12 France Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.13 Italy Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.14 Spain Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.15 China Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.16 Japan Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.17 Russia Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.18 India Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.19 Brazil Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 8.20 Rest of the World Allergic Rhinitis Drugs Market Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.1 Leading Companies in The Allergic Rhinitis Drug Market: Revenues ($m), 2016
Figure 9.2 ALK-Abelló: Allergic Rhinitis Drugs Forecast: Revenue ($m), AGR (%), 2016-2027
Figure 9.3 GlaxoSmithKline Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.4Johnson & Johnson Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.5 Kyowa Hakko Kirin: Allergic Rhinitis Drugs Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.6 Merck & Co: Allergic Rhinitis Drugs Revenue Forecast: Revenue ($m) and AGR (%), 2016-2027
Figure 9.7 Sanofi: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.8 Stallergenes Greer: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 9.9 UCB: Allergic Rhinitis Drugs Revenue Forecast ($m, AGR%), 2016-2027
Figure 11.1 Porter’s Five Forces Analysis of the Allergic Rhinitis Drugs Market, 2017
ActoGeniX
Adamis Pharmaceuticals
ALK- Abelló
Allergy Medical UK
Allergy Therapeutics
Almirall
Altana Pharma (Nycomed)
Anergis
Apotex
AstraZeneca
Atopix Therapeutics
Barr Laboratories
Bausch & Lomb
Belcher Pharmaceuticals
Biotech Tools
Catalent Pharma Solutions
Celsus Therapeutics
Dainippon Sumitomo
DBV Technologies
Dr Reddy’s Laboratories
Eddingpharm
Eleventa
Genzyme (Sanofi)
GlaxoSmithKline
Greer Laboratories
Hisamitsu Pharmaceutical Co
Hoechst AG
Human Genome Sciences
Intas Pharmaceuticals
Johnson & Johnson
Keldman Healthcare
Kyowa Hakko Kirin
Leti Pharma (Laboratorios Leti)
Lupin Pharmaceuticals
Meda Pharma
Medpointe Inc (Meda Pharma)
Merck & Co
Mitsubishi Tanabe Pharma
Mylan
Nippon Paper Group
Novartis
Omega Pharma
Perrigo
Pfizer
ProStrakan (Kyowa Hakko Kirin)
Reckitt Benckiser
Roxane Laboratories (Boehringer Ingelheim)
Sanofi
Schering-Plough (Merck)
Shionogi & Co Ltd
Stallergenes
Sun Pharmaceuticals
Sunovion Pharmaceuticals (Dainippon Sumitomo)
Takeda
Teva Pharmaceuticals
Trimel Pharmaceuticals
Ube Industries
UCB
ViiV Healthcare
Wockhardt
Ziarco Pharma
Organizations Mentioned in the Report
Allergy & Asthma Network
AllergyUK
American Academy of Allergy, Asthma and Immunology (AAAAI)
British Society for Allergy & Clinical Immunology (BSACI) [UK]
Farmácia Popular [Brazil]
Imperial College London
International Nurses Group In Immunodeficiencies
Japanese Ministry of Health, Labour and Welfare
Les Entreprises Du Médicament (Leem) [France]
National Development and Reform Commission (NDRC) [China]
National Pharmaceutical Pricing Authority (NPPA) [India]
PollenUK
The Pharmaceutical Research and Manufacturers of America (PhRMA)
The UK Health and Social Care Information Centre
Université Libre de Bruxelles [Belgium]
University of Leuven [Belgium]
US Attorney’s Office for the Eastern District of Pennsylvania
US Food and Drug Administration (FDA)
World Allergy Organisation
World Health Organisation (WHO)
Download sample pages
Complete the form below to download your free sample pages for Global Allergic Rhinitis Drugs Market 2017-2027Download sample pages
Complete the form below to download your free sample pages for Global Allergic Rhinitis Drugs Market 2017-2027Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Drug Delivery Technologies Market Report 2024-2034
The global Drug Delivery Technologies market is estimated at US$1,729.6 billion in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period 2024-2034.
23 April 2024
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
